Related Experiment Video
Updated: Jan 26, 2026

Intracranial Pressure Monitoring In Nontraumatic Intraventricular Hemorrhage Rodent Model
Published on: February 8, 2022
MRI predicts intracranial hemorrhage in patients who receive long-term oral anticoagulation
Joan Martí-Fàbregas1, Santiago Medrano-Martorell2, Elisa Merino2
1From the Department of Neurology (J.M.-F., L.P.-S., R.M., R.D.-M., A.M.-D., P.C.-R., E.J.-X.) and Epidemiology (I.G.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute, Barcelona; Departments of Radiology (S.M.-M.) and Neurology (A.R.-C.), Hospital del Mar-Parc de Salut Mar, Barcelona; Unitat RM IDI (E.M.) and Department of Neurosciences (M.H.-P.), Hospital Germans Trias i Pujol, Badalona; Department of Neurology (M.Z.), Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia, Italy; Department of Neurology (M.G.-C.), Hospital de Sant Joan Despí Moises Broggi, Sant Joan Despí, Spain; Department of Neurology (L. Lara), Hospital de León; Department of Neurology (A.B.), Hospital Universitari Son Espases, Palma de Mallorca; Department of Neurology (A.C.), Hospital de Valladolid; Department of Neurology (A.M.D.A.-B.), Hospital de Donostia; Department of Neurology (Y.B.), Hospital de Burgos; Department of Neurology (B.F.), Hospital Universitario La Paz, Universidad Autónoma de Madrid, Instituto de Investigación IdiPaz, Madrid; Department of Neurology (D. Cánovas), Hospital Parc Taulí, Sabadell; Department of Neurology (L. Llull), Hospital Clínic, Barcelona; Department of Neurology (B.Z.), Hospital de Navarra, Pamplona; Department of Neurology (M.F.), Hospital de Basurto, Bilbao; Department of Neurology (I.C.-N.), Hospital San Pedro de Alcántara, Cáceres; Department of Neurology (J.S.), Hospital Arnau de Vilanova, Lleida; Department of Neurology (D. Cocho), Hospital de Granollers; Department of Neurology (J.K.), F.Ass. Mutua Terrassa; Department of Neurology (E.P.), Hospital de Mataró; Department of Neurology (A.D.F.), Hospital Ramón y Cajal, Madrid; Department of Neurology (M.S.), Hospital La Rioja, Logroño; Department of Neurology (E.Z.-A.), Hospital Virgen del Rocío, Sevilla; Department of Neurology (J.Z.-B.), Hospital Verge de la Cinta, Tortosa; Department of Neurology (I.D.-M.), Hospital de Albacete; Department of Neurology (J.F.-D.), Centro Médico Asturias, Oviedo; Department of Neurology (A.L.), Hospital La Fe, Valencia; Department of Neurology (J.M.), Hospital Virgen de las Nieves, Granada; and Department of Neurology (M.R.-Y.), Hospital Santiago de Compostela, Santiago de Compostela, Spain. jmarti@santpau.cat.
Objective:
We tested the hypothesis that the risk of intracranial hemorrhage (ICH) in patients with cardioembolic ischemic stroke who are treated with oral anticoagulants (OAs) can be predicted by evaluating surrogate markers of hemorrhagic-prone cerebral angiopathies using a baseline MRI.
Methods:
Patients were participants in a multicenter and prospective observational study. They were older than 64 years, had a recent cardioembolic ischemic stroke, and were new users of OAs. They underwent a baseline MRI analysis to evaluate microbleeds, white matter hyperintensities, and cortical superficial siderosis. We collected demographic variables, clinical characteristics, risk scores, and therapeutic data. The primary endpoint was ICH that occurred during follow-up. We performed bivariate and multivariate Cox regression analyses.
Results:
We recruited 937 patients (aged 77.6 ± 6.5 years; 47.9% were men). Microbleeds were detected in 207 patients (22.5%), moderate/severe white matter hyperintensities in 419 (45.1%), and superficial siderosis in 28 patients (3%). After a mean follow-up of 23.1 ± 6.8 months, 18 patients (1.9%) experienced an ICH. In multivariable analysis, microbleeds (hazard ratio 2.7, 95% confidence interval [CI] 1.1-7, p = 0.034) and moderate/severe white matter hyperintensities (hazard ratio 5.7, 95% CI 1.6-20, p = 0.006) were associated with ICH (C index 0.76, 95% CI 0.66-0.85). Rate of ICH was highest in patients with both microbleed and moderate/severe WMH (3.76 per 100 patient-years, 95% CI 1.62-7.4).
Conclusion:
Patients taking OAs who have advanced cerebral small vessel disease, evidenced by microbleeds and moderate to severe white matter hyperintensities, had an increased risk of ICH. Our results should help to determine the risk of prescribing OA for a patient with cardioembolic stroke.
Clinicaltrialsgov Identifier:
NCT02238470.
Insights
Patients with cardioembolic stroke on oral anticoagulants (OAs) with microbleeds and white matter hyperintensities on MRI face a higher risk of intracranial hemorrhage (ICH). These findings aid in assessing OA prescription risks.
Area of Science:
- Neurology
- Radiology
- Cardiology
Background:
- Cardioembolic ischemic stroke patients on oral anticoagulants (OAs) face risks of intracranial hemorrhage (ICH).
- Predicting ICH risk is crucial for safe OA prescription in this population.
- Cerebral small vessel disease markers on MRI may indicate hemorrhagic risk.
Purpose of the Study:
- To test if baseline MRI markers of hemorrhagic-prone cerebral angiopathies can predict ICH risk in patients with cardioembolic ischemic stroke treated with OAs.
- To evaluate the association between MRI findings and subsequent ICH events.
Main Methods:
- Prospective observational study of 937 patients (>64 years) with recent cardioembolic ischemic stroke, new OA users.
- Baseline MRI assessed microbleeds, white matter hyperintensities (WMH), and superficial siderosis.
- Multivariate Cox regression analyzed ICH as the primary endpoint over a mean follow-up of 23.1 months.
Main Results:
- ICH occurred in 1.9% of patients during follow-up.
- Microbleeds (HR 2.7) and moderate/severe WMH (HR 5.7) were significantly associated with increased ICH risk.
- Patients with both microbleeds and moderate/severe WMH had the highest ICH rate (3.76 per 100 patient-years).
Conclusions:
- Advanced cerebral small vessel disease, indicated by microbleeds and moderate/severe WMH on MRI, increases ICH risk in OA-treated cardioembolic stroke patients.
- These MRI markers can inform risk-benefit assessments for OA therapy.
- Baseline MRI findings are valuable for personalized risk stratification in stroke patients.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Receiver Operating Characteristic Plot
Predicting Molecular Geometry
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Long-term Depression
Oral Cavity
Teeth: The teeth are the hardest structures in our bodies. Humans have two sets of teeth throughout their lifetime: deciduous (baby) teeth and permanent teeth. Each tooth consists of several parts: the crown (visible part), the root (embedded in the jaw), enamel (hard outer...

